insights_auto
Why is RARE down 4.30%?
Dive Deeperchevron_right
RARE:NASDAQ
Ultragenyx Pharmaceutical Inc
US$16.48
arrow_downward
-4.30%(-0.74) 1D
US$16.50
arrow_upward
+0.12% (+0.020)bedtimeAfter hours
Closed: ኖቬም 20, 4:00:03 ከሰዓት ጂ ኤም ቲ-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for RARE...
Open
US$16.94
High
US$17.35
Low
US$16.42
Mkt. cap
1.68 ቢ
Avg. vol.
3.67 ሚ
Volume
3.01 ሚ
52-wk high
US$39.89
52-wk low
US$12.73
EPS
-US$5.19
Beta
0.37
Shares outstanding
101.92 ሚ
No. of employees
1 ሺ
Open
US$16.94
High
US$17.35
Low
US$16.42
Mkt. cap
1.68 ቢ
Avg. vol.
3.67 ሚ
Volume
3.01 ሚ
52-wk high
US$39.89
52-wk low
US$12.73
EPS
-US$5.19
Beta
0.37
Shares outstanding
101.92 ሚ
No. of employees
1 ሺ
News stories
From web sources and news partners
WSJ
·
ከ1 ቀን በፊት
Dow, S&P 500 Poised to Close at a Correction
Yahoo Finance
·
ከ6 ሰዓቶች በፊት
In the Last Tech Bust, the S&P 500 Lost Money for a Decade. History Says Stocks With the Highest Yields Gained 5.4% a Year.
Beinsure
·
ከ11 ሰዓቶች በፊት
Vanguard S&P 500 ETF: How investing in VOO could build a $1 mn portfolio
Trefis
·
ከ20 ሰዓቶች በፊት
S&P 500 Movers | Winners: GPN, GIS, MKC | Losers: BE, NVDA, LITE
Profile
Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.
Ultragenyx is based in Novato, CA and Brisbane, CA and has a presence in the Boston area, including a gene therapy plant under construction as of 2021. The company’s Latin American headquarters is located in Miami.
Ultragenyx collaborates on product development with other companies including GeneTX, Kyowa Hakko Kirin, Mereo Biopharma and Daiichi Sankyo. Ultragenyx has three products Burosumab, Triheptanoin and Vestronidase alfa that have received FDA approval and several others currently in clinical trials. The company also holds the non-US commercial rights to Regeneron’s evinacumab-dgnb, which is approved by the FDA and EMA. Wikipedia
About Ultragenyx Pharmaceutical Inc
CEOEmil Kakkis
Employees1.37 ሺ
Founded2010
HeadquartersNovato, ካሊፎርኒያ, ዩናይትድ ስቴትስ
SectorHealth Care
IndustryBiotechnology
Websiteultragenyx.com